The United States Department of Health and Human Services, Office of Inspector General (“OIG”) recently released two unfavorable advisory opinions, OIG Advisory Opinion No. 25-04 and -08 (the “Opinions”) to medical device...more
The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory Opinion No. 24-12 (the “Opinion”) to a pharmaceutical manufacturer (the...more
On January 19, 2022, the Department of Health and Human Services, Office of Inspector General (“OIG”) released a favorable advisory opinion, OIG Advisory Opinion No. 22-01 (the “Opinion”), analyzing a proposed expansion of...more
2/15/2022
/ Advisory Opinions ,
Anti-Kickback Statute ,
Beneficiary Inducement ,
Civil Monetary Penalty ,
Customer-Loyalty Programs ,
Discount Pricing ,
Food & Drug Regulations ,
Low-Income Issues ,
Medicaid ,
Medicare Advantage ,
Medicare Part B ,
Medicare Part D ,
OIG ,
Patient Access ,
Pharmacies ,
Prescription Drug Coverage ,
Prescription Drugs ,
Remuneration ,
Sanctions ,
Statutory Interpretation